Pharmacogenomics Market to Reach USD 9.63 Billion by 2034, Growing at 8.16% CAGR: Polaris Market Research

According to a new report by Polaris Market Research, the global Pharmacogenomics market was valued at USD 4.75 billion in 2025 and is projected to reach USD 9.63 billion by 2034, expanding at a CAGR of 8.16% over the forecast period. The market stood at an estimated USD 5.13 billion in 2026. Growth is underpinned by rising adoption of precision medicine, expanding genetic sequencing capabilities, and accelerating investment in pharmacogenomics research and development across key disease areas.

What Is Driving Pharmacogenomics Market Growth?

Demand is climbing as the growing prevalence of chronic and genetically influenced disorders converges with rising investment in healthcare infrastructure. Manufacturers and end users are prioritizing precision medicine, pushing pharmacogenomics adoption across cancer, cardiovascular, and neurological disease areas. Polaris analysts note that North America's 39.47% share of the market in 2025 positions the region for sustained growth through 2034, with the sequencing segment emerging as the largest revenue contributor and personalized medicine posting the fastest incremental gains at an 8.7% CAGR.

Key Trends Shaping the Pharmacogenomics Industry

Pre-emptive Genetic Testing Gains Clinical Traction

Healthcare systems are increasingly adopting pre-emptive pharmacogenomic testing ahead of prescribing, reducing adverse drug reactions and enabling faster, safer treatment decisions across chronic disease management, a trend reinforcing demand for next-generation sequencing and genotyping platforms.

Regulatory and Clinical Guideline Frameworks Mature

Agencies such as the FDA increasingly require or recommend pharmacogenomic labeling on drugs where genetic variation meaningfully affects response, while clinical practice guidelines from bodies like the Clinical Pharmacogenetics Implementation Consortium continue to formalize genomics-informed prescribing across healthcare systems.

AI and Bioinformatics Accelerate Clinical Decision Support

Advancements in bioinformatics and AI-powered genomics analysis are enhancing the interpretation of complex genetic data, helping clinicians move from population-based prescribing toward truly personalized treatment recommendations, supporting broader adoption of pharmacogenomics-based clinical decision support tools.

👉 Explore The Complete Comprehensive Report Here: https://www.polarismarketresearch.com/industry-analysis/pharmacogenomics-market

Market Segmentation: Breaking Down the Pharmacogenomics Market

Polaris segments the Pharmacogenomics market by disease area, product & service, technology, application, end use, and region, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Disease Area

The cancer segment leads the disease-area category, reflecting pharmacogenomics' established role in oncology, where genomic profiling of tumors guides targeted therapy selection through companion diagnostics. Cardiovascular and neurological disease areas continue to expand as genetic markers for drug metabolism and toxicity risk become more clinically actionable.

By Technology

The sequencing segment held the largest market share of 38.6% in 2025, driven by growing use of next-generation sequencing (NGS) in the comprehensive analysis of an individual's genetic makeup. PCR and microarray technologies continue to support targeted, lower-cost genotyping applications across clinical and research settings.

By Application

Personalized medicine is expected to record the fastest CAGR of 8.7% during the forecast period as healthcare systems worldwide prioritize genetics-based treatment strategies to improve outcomes and minimize adverse drug reactions. Clinical research and drug discovery & preclinical development remain significant applications supporting pharmaceutical R&D pipelines.

By End Use

Pharmaceutical & biotechnology companies represent a leading end-use category, leveraging pharmacogenomics to de-risk drug development and support companion diagnostic strategies. Academic & research institutes and contract research organizations (CROs) continue to expand their role in pharmacogenomics-driven clinical research.

Regional Outlook: Where Is Pharmacogenomics Growing Fastest?

North America led the market in 2025 with a 39.47% share, supported by the presence of major pharmaceutical companies and research organizations, advanced healthcare infrastructure, and favorable reimbursement policies, while Asia Pacific is expected to post the fastest CAGR of 12.8% through 2034, driven by rapid healthcare investment and genetic diversity across China, Japan, India, and South Korea. Within North America, the United States remains the largest single market, holding 78.3% share of the regional market in 2025. Europe continues to expand alongside strengthening genomics-informed prescribing frameworks such as the EU's regulatory guidelines.

👉 Explore the Full Pharmacogenomics Market Report : https://www.polarismarketresearch.com/industry-analysis/pharmacogenomics-market/pricing

Competitive Landscape: Leading Pharmacogenomics Companies

Key players profiled in the report include Illumina, Inc., Thermo Fisher Scientific Inc., QIAGEN, and Roche Diagnostics, who are focusing on strategic collaborations, continuous product improvements, and partnership initiatives to strengthen market position across the sequencing and personalized medicine segments outlined above. Recent moves include Tempus AI's July 2026 national launch of its OneOme pharmacogenomics testing solution and Agilent Technologies' June 2025 unveiling of new mass spectrometry systems supporting drug discovery, both aimed at deepening share in the clinical PGx testing landscape.

Why It Matters for Stakeholders Evaluating Precision Medicine Investment

For stakeholders researching precision medicine market opportunities, this report benchmarks pharmacogenomics market share, segment-level data, and forecast figures by disease area, technology, application, and region to support sourcing, investment, and go-to-market decisions. It is built for diagnostics companies comparing platforms, investors sizing entry points, and strategy teams tracking companion diagnostics as a growth adjacency.

About Polaris Market Research

Polaris Market Research is a B2B syndicated market research and consulting firm offering 5,000+ published reports across 20+ industry verticals, delivering data-backed insights to help businesses make informed decisions.

More Trending Latest Reports By Polaris Market Research:

Attention Deficit Hyperactivity Disorder Market

Veterinary Clinical Trials Market

T4 DNA Ligase Market

Veterinary Clinical Trials Market

Substation Automation Market

Patient Scales Market

Explore the Benefits of the Pension Administration Software Market

U.S. Sterilization Monitoring Market